NO318827B1 - Krystallinsk, polymorf antisoppforbindelse, farmasoytiske preparater inneholdende en slik forbindelse og anvendelse av en slik forbindelse - Google Patents
Krystallinsk, polymorf antisoppforbindelse, farmasoytiske preparater inneholdende en slik forbindelse og anvendelse av en slik forbindelse Download PDFInfo
- Publication number
- NO318827B1 NO318827B1 NO20001779A NO20001779A NO318827B1 NO 318827 B1 NO318827 B1 NO 318827B1 NO 20001779 A NO20001779 A NO 20001779A NO 20001779 A NO20001779 A NO 20001779A NO 318827 B1 NO318827 B1 NO 318827B1
- Authority
- NO
- Norway
- Prior art keywords
- crystalline
- compound
- polymorphic form
- phenyl
- triazol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 38
- 230000000843 anti-fungal effect Effects 0.000 title description 4
- 229940121375 antifungal agent Drugs 0.000 title description 4
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims description 16
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 15
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 14
- 238000002329 infrared spectrum Methods 0.000 claims description 9
- 239000008188 pellet Substances 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- 206010017533 Fungal infection Diseases 0.000 claims description 6
- 208000031888 Mycoses Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000002904 solvent Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000000113 differential scanning calorimetry Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000001757 thermogravimetry curve Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000003517 fume Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002076 thermal analysis method Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- -1 contain inert Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94618397A | 1997-10-07 | 1997-10-07 | |
| PCT/US1998/020476 WO1999018097A1 (en) | 1997-10-07 | 1998-10-05 | Crystalline antifungal polymorph |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20001779D0 NO20001779D0 (no) | 2000-04-06 |
| NO20001779L NO20001779L (no) | 2000-06-06 |
| NO318827B1 true NO318827B1 (no) | 2005-05-09 |
Family
ID=25484068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20001779A NO318827B1 (no) | 1997-10-07 | 2000-04-06 | Krystallinsk, polymorf antisoppforbindelse, farmasoytiske preparater inneholdende en slik forbindelse og anvendelse av en slik forbindelse |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1021439B1 (cs) |
| JP (4) | JP2001519346A (cs) |
| KR (1) | KR100626109B1 (cs) |
| CN (1) | CN1125067C (cs) |
| AR (1) | AR015947A1 (cs) |
| AT (1) | ATE263163T1 (cs) |
| AU (1) | AU759982B2 (cs) |
| BR (1) | BR9812866A (cs) |
| CA (1) | CA2305803C (cs) |
| CO (1) | CO4970829A1 (cs) |
| CZ (1) | CZ299835B6 (cs) |
| DE (1) | DE69822859T2 (cs) |
| DK (1) | DK1021439T3 (cs) |
| ES (1) | ES2217594T3 (cs) |
| HU (1) | HU225233B1 (cs) |
| ID (1) | ID29290A (cs) |
| IL (1) | IL135331A (cs) |
| IN (1) | IN1998CH02232A (cs) |
| MX (1) | MX225999B (cs) |
| MY (1) | MY130126A (cs) |
| NO (1) | NO318827B1 (cs) |
| NZ (1) | NZ503662A (cs) |
| PE (1) | PE120499A1 (cs) |
| PH (1) | PH11998002606B1 (cs) |
| PL (1) | PL189317B1 (cs) |
| PT (1) | PT1021439E (cs) |
| SK (1) | SK285190B6 (cs) |
| TW (1) | TW589310B (cs) |
| WO (1) | WO1999018097A1 (cs) |
| ZA (1) | ZA989063B (cs) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2130540A1 (en) | 2008-06-02 | 2009-12-09 | Sandoz AG | Pharmaceutical compositions containing a crystalline form of posaconazole |
| EP2141159A1 (en) * | 2008-07-03 | 2010-01-06 | Sandoz AG | A Crystalline form of posaconazole |
| CA2767489A1 (en) | 2009-07-09 | 2011-01-13 | Sandoz Ag | A crystalline form of posaconazole |
| EP2571847B1 (en) | 2010-05-19 | 2016-09-21 | Sandoz AG | Process for the preparation of chiral hydrazides |
| US9206146B2 (en) | 2010-05-19 | 2015-12-08 | Sandoz Ag | Purification of posaconazole and of posaconazole intermediates |
| AU2011254654B2 (en) | 2010-05-19 | 2016-01-07 | Sandoz Ag | Process for the preparation of chiral triazolones |
| BR112012029226A2 (pt) | 2010-05-19 | 2015-10-20 | Sandoz Ag | processo para a preparação de um composto quiral, composto quiral cristalino, sal de hcl do composto quiral cristalino, composto quiral e uso do composto |
| WO2012172015A1 (en) | 2011-06-16 | 2012-12-20 | Sandoz Ag | Process for the preparation of a chiral compound |
| US9102664B2 (en) | 2011-09-19 | 2015-08-11 | Msn Laboratories Private Limited | Process for the preparation of triazole antifungal drug, its intermediates and polymorphs thereof |
| MX370849B (es) * | 2013-07-25 | 2020-01-08 | Sandoz Ag | Proceso mejorado para preparar la forma cristalina iv del posaconazol. |
| ITMI20132115A1 (it) * | 2013-12-18 | 2015-06-19 | Djada Pharmaceutical Sa | Una forma cristallina di posaconazolo |
| ITMI20132118A1 (it) * | 2013-12-18 | 2015-06-19 | Djada Pharmaceutical Sa | Una forma cristallina di posaconazolo |
| ITMI20132114A1 (it) | 2013-12-18 | 2015-06-19 | Djada Pharmaceutical Sa | Una forma cristallina di posaconazolo |
| ITMI20132117A1 (it) * | 2013-12-18 | 2015-06-19 | Djada Pharmaceutical Sa | Una forma cristallina di posaconazolo |
| JP6633072B2 (ja) | 2014-10-21 | 2020-01-22 | アリアド ファーマシューティカルズ，インコーポレーテッド | ５−クロロ−ｎ４−［２−（ジメチルホスホリル）フェニル］−ｎ２−｛２−メトキシ−４−［４−（４−メチルピペラジン−１−イル）ピペリジン−１−イル］フェニル｝ピリミジン−２，４−ジアミンの結晶形態 |
| CN104387374A (zh) * | 2014-10-21 | 2015-03-04 | 江苏恒盛药业有限公司 | 泊沙康唑晶型i的制备工艺 |
| CN104370894A (zh) * | 2014-10-21 | 2015-02-25 | 江苏恒盛药业有限公司 | 无定型泊沙康唑的制备工艺 |
| EP3331501B1 (en) | 2015-08-08 | 2019-09-11 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Gastro-resistant formulation containing posaconazole |
| DK3394045T3 (da) | 2015-12-24 | 2021-08-16 | Takeda Pharmaceuticals Co | Co-krystal, fremstillingsfremgangsmåde deraf og medikament som indeholder co-krystal. |
| EP3925601B1 (en) | 2016-02-26 | 2024-07-17 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor |
| CN105949278B (zh) * | 2016-03-30 | 2019-12-06 | 南京曼杰生物科技有限公司 | 一种取代的四氢呋喃水溶性衍生物及其应用 |
| WO2017032908A1 (en) | 2016-07-08 | 2017-03-02 | Synthon B.V. | Pharmaceutical composition comprising amorphous posaconazole |
| TR201620462A2 (tr) | 2016-12-31 | 2018-07-23 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ |
| TR201722493A2 (tr) | 2017-12-28 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Posakonazol i̇çeren kati farmasöti̇k kompozi̇syon |
| EP4196096A1 (en) | 2020-08-13 | 2023-06-21 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Gastro-resistant high-strength formulation containing posaconazole |
| EP4091604B1 (en) | 2021-11-25 | 2024-04-03 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granules containing posaconazole |
| AU2022324717A1 (en) | 2021-11-25 | 2024-06-13 | Alfred E. Tiefenbacher (Gmbh Und Co. Kg) | Granules containing posaconazole |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL103558A0 (en) * | 1991-10-30 | 1993-03-15 | Schering Corp | Tri-substituted tetrahydrofuran antifungals |
| NZ278713A (en) * | 1993-12-21 | 1997-12-19 | Schering Corp | Piperazine- and di-triazole-containing tetrahydrofuran antifungals |
| HU227281B1 (en) * | 1994-01-24 | 2011-01-28 | Janssen Pharmaceutica Nv | Watersoluble azole antifungals, process for their preparation intermediates, and pharmaceutical compositions containing the compounds |
| US5625064A (en) * | 1995-04-19 | 1997-04-29 | Schering Corporation | Process for the preparation of triazolones |
| AR002751A1 (es) * | 1995-06-02 | 1998-04-29 | Schering Corp | Antifungicos de tetrahidrofurano, composiciones farmaceuticas que los contienen y el uso de los compuestos para preparar composiciones farmaceuticas utiles para el tratamiento de infecciones fungicas |
-
1998
- 1998-10-05 WO PCT/US1998/020476 patent/WO1999018097A1/en active IP Right Grant
- 1998-10-05 CZ CZ20001264A patent/CZ299835B6/cs not_active IP Right Cessation
- 1998-10-05 AU AU97803/98A patent/AU759982B2/en not_active Expired
- 1998-10-05 CO CO98057733A patent/CO4970829A1/es unknown
- 1998-10-05 ES ES98951994T patent/ES2217594T3/es not_active Expired - Lifetime
- 1998-10-05 NZ NZ503662A patent/NZ503662A/xx not_active IP Right Cessation
- 1998-10-05 PE PE1998000942A patent/PE120499A1/es not_active IP Right Cessation
- 1998-10-05 BR BR9812866-3A patent/BR9812866A/pt not_active Application Discontinuation
- 1998-10-05 DE DE69822859T patent/DE69822859T2/de not_active Expired - Lifetime
- 1998-10-05 CA CA002305803A patent/CA2305803C/en not_active Expired - Lifetime
- 1998-10-05 JP JP2000514908A patent/JP2001519346A/ja not_active Withdrawn
- 1998-10-05 CN CN98811886A patent/CN1125067C/zh not_active Expired - Lifetime
- 1998-10-05 PT PT98951994T patent/PT1021439E/pt unknown
- 1998-10-05 KR KR20007003709A patent/KR100626109B1/ko not_active Expired - Lifetime
- 1998-10-05 SK SK512-2000A patent/SK285190B6/sk not_active IP Right Cessation
- 1998-10-05 IL IL13533198A patent/IL135331A/xx not_active IP Right Cessation
- 1998-10-05 EP EP98951994A patent/EP1021439B1/en not_active Expired - Lifetime
- 1998-10-05 AR ARP980104957A patent/AR015947A1/es not_active Application Discontinuation
- 1998-10-05 PL PL98339659A patent/PL189317B1/pl unknown
- 1998-10-05 AT AT98951994T patent/ATE263163T1/de active
- 1998-10-05 ZA ZA989063A patent/ZA989063B/xx unknown
- 1998-10-05 HU HU0004899A patent/HU225233B1/hu unknown
- 1998-10-05 ID IDW20000632A patent/ID29290A/id unknown
- 1998-10-05 DK DK98951994T patent/DK1021439T3/da active
- 1998-10-06 MY MYPI98004576A patent/MY130126A/en unknown
- 1998-10-06 PH PH11998002606A patent/PH11998002606B1/en unknown
- 1998-10-06 IN IN2232CH1998 patent/IN1998CH02232A/en unknown
- 1998-10-06 TW TW087116562A patent/TW589310B/zh not_active IP Right Cessation
-
2000
- 2000-04-06 MX MXPA00003404 patent/MX225999B/es active IP Right Grant
- 2000-04-06 NO NO20001779A patent/NO318827B1/no not_active IP Right Cessation
-
2008
- 2008-01-04 JP JP2008000110A patent/JP2008106075A/ja not_active Withdrawn
-
2012
- 2012-05-18 JP JP2012114725A patent/JP2012153730A/ja active Pending
- 2012-05-18 JP JP2012114724A patent/JP2012153729A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO318827B1 (no) | Krystallinsk, polymorf antisoppforbindelse, farmasoytiske preparater inneholdende en slik forbindelse og anvendelse av en slik forbindelse | |
| US6713481B1 (en) | Crystalline antifungal polymorph | |
| EP2141159A1 (en) | A Crystalline form of posaconazole | |
| AU2002255017B2 (en) | Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic acid | |
| US6506767B1 (en) | 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine | |
| EP1000027A1 (en) | Thermodynamically stable modification of 1-(4-carbazolyloxy)-3- 2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it | |
| PL191943B1 (pl) | Odmiana krystaliczna A 1-(2,6-difluorobenzylo)-1H-1,2,3-triazolo-4-karboksyamidu, preparat farmaceutyczny zawierający taką odmianę krystaliczną oraz zastosowanie takiej odmiany krystalicznej | |
| WO1999001450A1 (en) | POLYMORPHS OF 8-CHLORO-6, 11-DIHYDRO-11- (4-PIPERIDYLIDENE) -5H-BENZO[5,6] CYCLOHEPTA[1,2-b]PYRIDINE | |
| KR102566383B1 (ko) | 3-하이드록시-비스-벤질옥시-6-벤질옥시메틸-2-페닐-2-옥소-2λ5-[1,2]옥사포스피난의 결정질 다형 형태 | |
| CA2494288A1 (en) | Novel salt and polymorphs of desloratadine hemifumarate | |
| HK1029588B (en) | Crystalline antifungal polymorph | |
| WO1999018111A1 (en) | Crystalline antifungal glycine ester polymorph | |
| MXPA00000133A (en) | POLYMORPHS OF 8-CHLORO-6, 11-DIHYDRO-11- (4-PIPERIDYLIDENE) -5H-BENZO[5,6]CYCLOHEPTA[1, 2-b]PYRIDINE | |
| HK1072772B (en) | Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic | |
| CZ12566U1 (cs) | Amlodipinhemimaleát a farmaceutický prostředek |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MERCK SHARP AND DOHME CORP Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US |
|
| MK1K | Patent expired |